Insider Selling: Neurocrine Biosciences CEO Sells 3,750 Shares of Stock (NBIX)
Neurocrine Biosciences (NASDAQ:NBIX) CEO Kevin Charles Gorman sold 3,750 shares of the stock on the open market in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $18.57, for a total transaction of $69,637.50. Following the completion of the sale, the chief executive officer now directly owns 180,952 shares of the company’s stock, valued at approximately $3,360,279. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on NBIX shares. Analysts at Nomura initiated coverage on shares of Neurocrine Biosciences in a research note to investors on Wednesday, January 8th. They set a “buy” rating on the stock. Separately, analysts at Morgan Stanley downgraded shares of Neurocrine Biosciences from an “overweight” rating to an “equal weight” rating in a research note to investors on Wednesday, January 8th. They now have a $16.00 price target on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Neurocrine Biosciences from $16.00 to $23.00 in a research note to investors on Wednesday, January 8th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Neurocrine Biosciences currently has an average rating of “Buy” and a consensus price target of $18.73.
Neurocrine Biosciences (NASDAQ:NBIX) traded down 2.61% on Monday, hitting $18.65. The stock had a trading volume of 1,568,737 shares. Neurocrine Biosciences has a 52 week low of $8.57 and a 52 week high of $19.34. The stock’s 50-day moving average is $10.89 and its 200-day moving average is $11.96. The company’s market cap is $1.256 billion.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.03. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.79 million. During the same quarter in the previous year, the company posted ($0.05) earnings per share. The company’s revenue for the quarter was down 92.2% on a year-over-year basis. On average, analysts predict that Neurocrine Biosciences will post $-0.70 earnings per share for the current fiscal year.
Neurocrine Biosciences, Inc (NASDAQ:NBIX) discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.